Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax with Ivosidenib and Azacitidine in IDH1-mutated AML
NCT07075016Phase 3Recruiting
- Sponsor
- HOVON
- Start
- Aug 2025
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 16
01
Overview
A Phase 3 trial of venetoclax in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by HOVON. Started Aug 2025; status: recruiting.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT07075016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07075016.